$19.29
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing
Overview
52-week range
$5.55
$13
100% of range
Avg surprise (last 3)
+1.1%
Avg reaction (last 2)
+2.4%
50% positive
Latest IV / EM
203%
EM ±46.4% · $20 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.26 | $-0.30 | +13.3% | +3.7% | +9.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.44 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.30 | $-0.25 | -20.0% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.27 | $-0.30 | +10.0% | — | -4.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.25 | -$0.30 | +16.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-8M | $-7M | $-6M | — | $-4M | $-5M |
| Net income | $-6M | — | $-7M | $-6M | $-5M | — | $-4M | $-4M |
| EPS (diluted) | $-0.26 | — | $-0.44 | $-0.30 | $-0.27 | — | $-0.24 | $-0.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $25M | $32M | $35M | $27M | $30M | $19M | $17M | $18M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $25M | $32M | $36M | $27M | $30M | $19M | $17M | $18M |
| Total assets | $25M | $32M | $36M | $27M | $30M | $19M | $17M | $18M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $13M | $12M | $10M | $9M | $9M | $6M | $6M |
| Total equity | $14M | $18M | $24M | $17M | $21M | $10M | $11M | $13M |